Aptevo Therapeutics Sells IXINITY Hemophilia B Therapy to Medexus Pharmaceuticals

March 6, 2020

The following is an excerpt from a press release from Aptevo Therapeutics. Read the press release in its entirety here. Aptevo Therapeutics Inc. , a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, announced it has completed the sale of its marketed recombinant factor IX therapeutic, IXINITY庐 […]

Sign up for E-mails, Dateline Magazine, and other ways to stay connected.